Enalapril and valsartan improve cyclosporine A-induced vascular dysfunction in spontaneously hypertensive rats

European Journal of Pharmacology

Volumn 398, Issue 1, 2000, Pages 99-106

  Lassila, Markus ^a   Finckenberg, Piet ^a   Pere, Anna Kaisa ^a   Vapaatalo, Heikki ^a   Nurminen, Marja Leena ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Angiotensin II; Cyclosporine A; Enalapril; Na+; Valsartan; Vascular response

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN; CYCLOSPORIN A; ENALAPRIL; NITROPRUSSIDE SODIUM; NORADRENALIN; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HYPERTENSION; MALE; MESENTERIC ARTERY; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL ARTERY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR DISEASE;

ACETYLCHOLINE; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BODY WEIGHT; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENALAPRIL; HYPERTENSION; MALE; MESENTERIC ARTERIES; NITROPRUSSIDE; NOREPINEPHRINE; RATS; RATS, INBRED SHR; RENAL ARTERY; SYSTOLE; TETRAZOLES; VALINE; VASOCONSTRICTION; VASODILATION;

EID: 0034625522     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00282-X     Document Type: Article

References (41)

1. Abassi Z.A., Pieruzzi F., Nakhoul F., Keiser H.R. Effects of cyclosporin A on the synthesis, excretion, and metabolism of endothelin in the rats. Hypertension. 27:1996;1140-1148.
2. Auch-Schwelk W., Bossaller C., Götze S., Thelen J., Fleck E. Endothelin and vascular smooth muscle function after chronic treatment with cyclosporin A. J. Cardiovasc. Pharmacol. 21:1993;435-440.
3. Auch-Schwelk W., Duske E., Hink U., Betz M., Unkelbach M., Fleck E. Vasomotor responses in cyclosporin A-treated rats after chronic angiotensin blockade. Hypertension. 23:1994;832-837.
4. Burdmann E.A., Andoh T.F., Nast C.C., Evan A., Connors B.A., Coffman T.M., Lindsley J., Bennett W.M. Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am. J. Physiol. 269:1995;F491-F499.
5. Busse R., Fleming I. The endothelial organ. Curr. Opin. Cardiol. 8:1994;719-727.
6. Chrysant S.G. Vascular remodelling: the role of angiotensin converting enzyme inhibitors. Am. Heart J. 135:1998;S21-S30.
7. Diederich D., Yang Z., Lüscher T.F. Chronic cyclosporine therapy impairs endothelium-dependent relaxation in the renal artery of the rat. J. Am. Soc. Nephrol. 2:1992;1291-1297.
8. Diederich D., Skopec J., Diederich A., Dai F.-X. Cyclosporine produces endothelial dysfunction by increased production of superoxide. Hypertension. 23:1994;957-961.
9. Edwards B.D., Chalmers R.J., O'Driscoll J.B., Mitchell D.M., Smith R.J., Lawson R.S., Testa H.J., Ballardie F.W. Angiotensin II as a risk factor for cyclosporin nephrotoxicity in patients with psoriasis. Clin. Nephrol. 41:1994;350-356.
10. Epstein A., Beall A., Wynn J., Mulloy L., Brophy M. Cyclosporine, but not FK506, selectively induces renal and coronary artery smooth muscle contraction. Surgery. 123:1998;456-460.
11. Faulds D., Goa K.L., Benfield P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs. 45:1993;953-1040.
12. 2+. Circ. Res. 74:1994;477-484.
13. Gohlke P., Linz W., Scholkens B., VanEven P., Martorana P., Unger T. Vascular and cardiac protection by ramipril in spontaneously hypertensive rats: prevention versus regression study. Clin. Pract. Symp. (Suppl. 84):1996;1-10.
14. 1A receptor in cyclosporine induced hypertensive rats. Eur. J. Pharmacol. 248:1993;341-344.
15. Kon V., Huntley T.E., Fogo A. Combined antagonism of endothelin A/B receptors links endothelin to vasoconstriction whereas angiotensin II effects fibrosis. Transplantation. 60:1995;89-95.
16. Khairallah P.A., Page I.H., Bumpus F.M., Turker R.K. Angiotensin tachyphylaxis and its reversal. Circ. Res. 19:1966;247-254.
17. Kim H.S., Kim D.H., Kang S.W., Choi K.H., Lee H.Y., Han D.S., Lee Y.H., Kang B.S. L-arginine restores suppressed acetylcholine-induced endothelium-dependent vascular relaxation in cyclosporine A-treated rats. Transplant. Proc. 28:1996;1372-1374.
18. Kristian T., Siesjö B.K. Calcium in ischemic cell death. Stroke. 29:1998;705-718.
19. Kurtz A., Della Bruna R., Kuhn K. Cyclosporine A enhances renin secretion and production in isolated juxtaglomerular cells. Kidney Int. 33:1988;947-953.
20. Lanese D.M., Conger J.D. Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J. Clin. Invest. 91:1993;2144-2149.
21. Lanese D.M., Falk S.A., Conger J.D. Sequential agonist activation and site-specific mediation of acute cyclosporine constriction in rat renal arteriols. Transplantation. 58:1994;1371-1378.
22. Linz W., Schölkens B.A. A specific B2-bradykinin receptor antagonis HOE 140 abolishes the antihypertrophic effect of ramipril. Br. J. Pharmacol. 105:1992;771-772.
23. Mason J. Pharmacology of cyclosporine (Sandimmune): Part VII. Pathophysiology and toxicology of cyclosporine in humans and animals. Pharmacol. Rev. 42:1989;423-434.
24. Mervaala E.M.A., Pere A.-K., Lindgren L., Laakso J., Teräväinen T.-L., Karjala K., Vapaatalo H., Ahonen J., Karppanen H. Effects of dietary sodium and magnesium on cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats. Hypertension. 29:1997;822-827.
25. Mervaala E.M.A., Lassila M., Vaskonen T., Krogerus L., Lähteenmäki T., Vapaatalo H., Karppanen H. Effects of ACE inhibition on cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on high sodium diet. Blood Pressure. 8:1999;49-56.
26. Mikkelsen E.O., Poulsen S.H., Nyborg N.C.B., Korsgaard N., Sehested J. Difference between aortic and renal vascular reactivity in cyclosporine A treated rats and the effect of cicletanine. Naunyn-Schmiedeberg's Arch. Pharmacol. 343:1992;356-361.
27. Oriji G.K., Keiser H.R. Role of nitric oxide in cyclosporine A-induced hypertension. Hypertension. 32:1998;849-855.
28. Pere A.-K., Krogerus L., Mervaala E.M.A., Laakso J., Karppanen H., Inkinen K., Pere P., Ahonen J., Vapaatalo H., Lindgren L. Detrimental effect of dietary sodium and beneficial effect of dietary magnesium on glomerular changes in cyclosporin-A-treated spontaneously hypertensive rats. Nephrol., Dial., Transplant. 13:1998;904-910.
29. Pichler R.H., Franceschini N., Young B.A., Hugo C., Andoh T.F., Burdmann E.A., Shankland S.J., Alpers C.E., Bennett W.M., Couser W.G., Johnson R.J. Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J. Am. Soc. Nephrol. 6:1995;1186-1196.
30. 1 antagonists. J. Cardiovasc. Pharmacol. 26:1995;66-72.
31. Rego A., Vargas R., Wroblewska B., Foegh M.L., Ramwell P.W. Attenuation of vascular relaxation and cyclic GMP responses by cyclosporin A. J. Pharmacol. Exp. Ther. 252:1990;165-171.
32. Ressureicao F.A.M.S., Ballejo G., Salgado M.C.O., Ferraz A.S. Effecs of cyclosporine administration on vascular reactivity of the mesenteric bed. Transplant. Proc. 27:1995;1806-1808.
33. Rossi N.F., Churchill P.C., McDonald F.D., Ellis V.R. Mechanism of cyclosporine A-induced renal vasoconstriction in the rat. J. Pharmacol. Exp. Ther. 250:1989;896-901.
34. Roullet J.-B., Xue H., Burdman J., Chapman J., McCarron D.A., Bennett W.M. Cardiovascular consequences of immunosuppressive drug treatment: comparative study of cyclosporine A and cyclosporine G. Transplant. Proc. 27:1995;346-347.
35. Stephan D., Billing A., Krieger J.-P., Grima M., Fabre M., Hofner M., Imbs J.-L., Barthelmembs M. Endothelium-dependent relaxation in the isolated rat kidney: impairment by cyclosporine A. J. Cardiovasc. Pharmacol. 26:1995;859-868.
36. Takeda Y., Miyamori I., Yoneda T., Takeda R. Increased concentration of endothelin messenger RNA in the mesenteric arteries of cyclosporine-induced hypertensive rats. Am. J. Hypertens. 6:1993;427-430.
37. Takeda Y., Miyamori I., Wu P., Yoneda T., Furukawa K., Takeda R. Effects of an endothelin receptor antagonist in rats with cyclosporine-induced hypertension. Hypertension. 26:1995;932-936.
38. Textor S.C., Canzanello V.J., Taler S.J., Wilson D.J., Schwartz L.L., Augustine J.E., Raymer J.M., Romero J.C., Wiesner R.H., Krom R.A.F, Burnett J.C. Cyclosporine-induced hypertension after transplantation. Mayo Clin. Proc. 69:1994;1182-1193.
39. Verbeke M., Van de Voorde J., de Ridder L., Lameire N. Regional differences in vasculotoxic effects of cyclosporin in rats. Can. J. Physiol. Pharmacol. 73:1995;1661-1668.
40. Yamamoto S., Hayashi N., Kometani M., Nakao K., Inukai T. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 1st communication: antihypertensive effect of valsartan in hypertensive models. Arzneim.-Forsch. 47:1997;604-612.
41. Zoja C., Furci L., Ghilardi G., Zilio P., Benigni A., Remuzzi G. Cyclosporine-induced endothelial cell injury. Lab. Invest. 55:1986;455-462.